Levitra Pills

A new study done by the manufacturers of the erectile dysfunction drug Levitra namely Bayer Schering Pharma adds to the weight of evidence which shows that their impotence medication is “highly efficacious” for men suffering from erectile problems. The study also noted that it was especially effective after surgery for prostate cancer known as nerve-sparing prostatectomy.
The study was designed to examine whether the Levitra drug would be effective when taken at a particular time every night as a prophylactic treatment as opposed to the effectiveness of the Levitra drug when it is taken on demand. In line with correct practices for drug trials the study was conducted in many different locations with a placebo controlled, double blind randomised format. Almost 450 men took part in the clinical trials for over a year making it the largest study of its kind.

The thinking behind the study was explained by Professor Francesco Montorsi at the University Vita Salute San Raffaele who said the idea was to examine the best way for men to use the Levitra drug after they had undergone radical prostate surgery.

The results which were collected over a nine month period saw that men who used Levitra on demand had a 46 percent success rate for satisfactory sexual intercourse compared to a 34.5 percent success rate for those men who took Levitra every night at the same time. Twenty five percent of men who took a placebo tablet also reported normal erectile function when based on the International Index of Erectile Function standard.

The researchers therefore maintained that the idea of treating erectile dysfunction in men following prostate cancer surgery by taking a daily dose of Levitra was not as effective as taking the Levitra on demand. The researchers said nevertheless that this study adds to the weight of evidence that confirms the specific effectiveness of Levitra as a treatment to cure erectile dysfunction in men following prostate surgery.

A recent UK research project for the erectile dysfunction medication known as Levitra has produced results that show that the Levitra is not only enhancing the sexual function and pleasure of men but also that it can play a part in the enhancement of sexual function of women. The research confirms a trend in thinking that it is women who benefit from erectile dyfunction medication as much as men if not more.

The research project in the South West of England  involved 260 participants who admitted to some form of erectile dysfunction. The men were either given Levitra or a dud placebo pill. The study that took place over 3 months involved detailed questionnaires about sexual function and satisfaction from both the men and women at monthly intervals.

The first finding that was reported was an 81% betterment in erections for those taking the Levitra medication compared to only 30% with the dud placebo pill. Erectile dysfunction medication is known to produce high figures of supposed improvemnet with placebo pills, thus explaining why so many worthless traditional remedies continue to be used.

The participants were asked in their questionnaires whether Levitra had an effect on sexual function in both the men and women in the following areas. They were  orgasm satisfaction, sexual confidence, sexual pleasure, ease of erection, satisfaction of erection and satisfaction of the medication.

Sixty percent of men taking the Levitra reported improved orgasm satisfaction compared to 32% of those taking the placebo. Females reported 56% and 32% improvement of orgasm satisfaction respectively for Levitra and placebo.

Levitra also improved the sexual confidence of both men and women over the study period with figures of 62% for men and 59% for women. The placebo increased confidence by 34% in men and 30% in women. Sexual pleasure received a boost with 67% of men and 64% of women reporting positively on that compared to 44% and 38% with the placebo.

The perception by which ease of erection was improved was 64% for men and 60% for women for Levitra users and 41% and 37% for placebo users. The satisfaction with erection figures were 60% and 58% for Levitra and 28% and 27% for placebo users. Overall satisfaction with Levitra was 62% and 58% for those actually using it and those who thought that they were using it reported 31% and 30% respectively.

The difference in improvement of sexual funtion for men and women was minimal suggesting that Levitra is as much a sexual function drug for women as it is for men.

Levitra the least known erectile dysfunction medication has been used in a number of medical trials recently done on the heart. The researchers noted that not only did the use of the vardenafil (the active ingredient of Levitra) help when administered before a heart attack but also when given after the heart attack.
In the research human hearts were not studied due to the inherent dangers but animals were used that mimic the human heart closely. It was noted that the Levitra erectile dysfunction drug was more effective in preventing damage to the heart and preventing a heart attack in the first place then nitro-glycerine that is commonly used. The research that was done at Virginia Commonwealth University in the United States concluded that in the future the impotence drug Levitra could work as a heart attack preventer and heart strengthener in men who were at risk due to cardio problems.

After a heart attack the heart muscle is often damaged and this can be a big problem when it comes to the recovery. The animals therefore who were given the Levitra recovered more quickly than those that were not. Viagra the more famous impotence medication was also used in this study and was seen to have an identical effect on the heart muscles as Levitra did. The study has already been made public in the Journal of Molecular and Cellular Cardiology and is likely to fuel a whole new set of studies on the connection and use of erectile dysfunction medication on the heart.

If research on the heart and Levitra proves to be conclusive and useful then the earnings for Abbott Laboratories that make Levitra could be enormous and could overtake the amount that they make from selling the drug to men with erectile difficulties. Ukmedix News will be looking out for more research in this regard.